Hospital
Ahmc Greater El Monte Community
Ahmc Greater El Monte Community was paid $9.17M by Medicaid between Jan 2018 and Dec 2024, across 160 billing codes. Its largest line is 0450, Emergency room services — 25% of everything it billed.
33Billing provider infoAHMC GREATER EL MONTE COMMUNITY
SOUTH EL MONTE, CA 91733
SOUTH EL MONTE, CA 91733
33aNPI1346232881assigned 08/19/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$9.17M
24GClaims429,651
24DCodes billed160
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#189 of 410
Median peer was paid$6.90M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MARSH, LINDA controls 11+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 65,896 | $1.30M | |
| 2019 | 62,527 | $1.55M | |
| 2020 | 45,304 | $938K | |
| 2021 | 42,025 | $987K | |
| 2022 | 62,741 | $1.45M | |
| 2023 | 77,020 | $1.60M | |
| 2024incomplete | 74,138 | $1.35M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 25% | 60,426 | 54,959 | $2.33M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 8.4% | 6,468 | 6,268 | $765K |
| 70450 | Computed tomography, head or brain; without contrast material | 6.8% | 6,405 | 6,231 | $625K |
| Z7502 | 5.7% | 14,298 | 14,037 | $527K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 5.3% | 10,621 | 9,704 | $484K |
| 80053 | Comprehensive metabolic panel | 2.9% | 19,835 | 18,408 | $263K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.8% | 13,034 | 12,252 | $260K |
| 99199 | Unlisted special service, procedure or report | 2.8% | 7,170 | 6,667 | $256K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.4% | 3,925 | 3,746 | $216K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.3% | 5,012 | 4,817 | $210K |
| 71045 | Radiologic examination, chest; single view | 1.9% | 15,507 | 14,842 | $177K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.9% | 8,438 | 8,046 | $172K |
148 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.7% | 23,720 | $160K |
| J3490 | Unclassified drugs | 1.7% | 23,400 | $157K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.6% | 3,027 | $149K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.6% | 2,701 | $146K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.5% | 1,166 | $135K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 1.4% | 2,087 | $125K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.4% | 4,240 | $125K |
| Z7610 | 1.3% | 8,697 | $119K | |
| 99283 | Emergency room visit (moderate) | <1% | 1,276 | $87K |
| 0250 | <1% | 15,624 | $75K | |
| 84484 | <1% | 9,130 | $73K | |
| 80306 | <1% | 4,906 | $73K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,600 | $72K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,918 | $65K |
| 0270 | <1% | 14,747 | $63K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,877 | $59K |
| 83690 | <1% | 9,527 | $55K | |
| 81001 | <1% | 15,059 | $51K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,167 | $47K |
| 0301 | <1% | 831 | $44K | |
| 99284 | Emergency room visit (serious) | <1% | 415 | $40K |
| 83735 | <1% | 6,937 | $40K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,581 | $38K |
| 84703 | <1% | 4,773 | $37K | |
| 83880 | <1% | 2,171 | $36K | |
| 90715 | <1% | 1,183 | $36K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,626 | $31K |
| 87040 | <1% | 1,867 | $31K | |
| 74018 | <1% | 1,073 | $31K | |
| 87088 | <1% | 7,881 | $30K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 285 | $26K |
| 73610 | <1% | 1,288 | $26K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,418 | $26K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 135 | $24K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 546 | $23K |
| 73630 | <1% | 1,196 | $22K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,548 | $22K |
| 0272 | <1% | 3,628 | $21K | |
| 73130 | <1% | 845 | $20K | |
| 70486 | <1% | 161 | $19K | |
| 73030 | <1% | 954 | $19K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 419 | $19K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,821 | $17K |
| 72100 | <1% | 669 | $16K | |
| 0271 | <1% | 3,948 | $16K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,292 | $15K |
| 85730 | <1% | 2,934 | $14K | |
| 93971 | <1% | 175 | $14K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,363 | $13K |
| 83605 | <1% | 1,655 | $13K | |
| 82948 | <1% | 2,227 | $12K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,057 | $12K |
| 85610 | <1% | 2,956 | $12K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 266 | $12K |
| 94660 | <1% | 219 | $10K | |
| 73564 | <1% | 419 | $10K | |
| 82550 | <1% | 1,911 | $9K | |
| 76801 | <1% | 158 | $9K | |
| 85379 | <1% | 1,186 | $8K | |
| 0360 | <1% | 43 | $8K | |
| 87186 | <1% | 1,413 | $8K | |
| A4649 | Surgical supply; miscellaneous | <1% | 1,857 | $8K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,338 | $8K |
| 73560 | <1% | 442 | $8K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,710 | $7K |
| J1815 | Injection, insulin, per 5 units | <1% | 536 | $6K |
| 84702 | <1% | 469 | $6K | |
| 73110 | <1% | 278 | $6K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,201 | $6K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 136 | $5K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 272 | $5K |
| 72131 | <1% | 37 | $5K | |
| 85027 | <1% | 1,098 | $5K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,094 | $5K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 27 | $4K |
| 87071 | <1% | 1,387 | $4K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 29 | $4K |
| 0710 | <1% | 52 | $4K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 117 | $4K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 802 | $4K |
| 82248 | <1% | 1,057 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 746 | $3K |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 362 | $3K |
| 87420 | <1% | 450 | $3K | |
| 81003 | <1% | 975 | $2K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 82 | $2K |
| 82805 | <1% | 153 | $2K | |
| 94664 | <1% | 301 | $2K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 435 | $2K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 104 | $2K |
| 12001 | <1% | 69 | $2K | |
| 85007 | <1% | 932 | $2K | |
| 86901 | <1% | 508 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 224 | $2K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 443 | $2K |
| 93970 | <1% | 15 | $2K | |
| 73080 | <1% | 90 | $2K | |
| 0762 | <1% | 41 | $2K | |
| 71010 | <1% | 73 | $1K | |
| 96367 | <1% | 39 | $1K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,223 | $940.58 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 199 | $803.95 |
| 29126 | <1% | 54 | $779.83 | |
| 36600 | <1% | 221 | $774.60 | |
| 82150 | <1% | 140 | $706.41 | |
| Z9725 | <1% | 16 | $688.48 | |
| 93041 | <1% | 112 | $587.40 | |
| 73140 | <1% | 77 | $576.70 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 1,231 | $576.36 |
| 73590 | <1% | 39 | $533.16 | |
| 86738 | <1% | 49 | $374.77 | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 13 | $370.80 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 113 | $368.92 |
| 80061 | Lipid panel | <1% | 76 | $368.06 |
| 29131 | <1% | 27 | $363.62 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 19 | $322.88 |
| 0320 | <1% | 66 | $286.24 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 28 | $276.60 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 95 | $271.55 |
| 86900 | <1% | 96 | $258.67 | |
| 76937 | <1% | 13 | $239.32 | |
| 72040 | <1% | 14 | $233.80 | |
| 80320 | <1% | 28 | $220.50 | |
| 99070 | <1% | 76 | $191.74 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 75 | $189.21 |
| J2704 | Injection, propofol, 10 mg | <1% | 33 | $169.13 |
| 29515 | <1% | 12 | $142.32 | |
| 73090 | <1% | 12 | $127.27 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 15 | $84.64 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 33 | $80.36 |
| 96376 | <1% | 14 | $78.90 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 16 | $76.64 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 16 | $59.75 |
| 82009 | <1% | 17 | $54.70 | |
| 87070 | <1% | 13 | $49.99 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 14 | $48.86 |
| 86140 | <1% | 16 | $43.96 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 35 | $3.86 |
| A0425 | Ground mileage, per statute mile | 0% | 201 | $0.00 |
| 0637 | 0% | 189 | $0.00 | |
| A0424 | Extra ambulance attendant, ground (als or bls) or air (fixed or rotary winged); (requires medical review) | 0% | 46 | $0.00 |
| E0601 | Continuous positive airway pressure (cpap) device | 0% | 83 | $0.00 |
| 0760 | 0% | 18 | $0.00 | |
| A0429 | Emergency ambulance ride, basic life support | 0% | 50 | $0.00 |
| A0398 | Als routine disposable supplies | 0% | 31 | $0.00 |
| E0562 | Humidifier, heated, used with positive airway pressure device | 0% | 124 | $0.00 |
| A0427 | Emergency ambulance ride, advanced life support | 0% | 71 | $0.00 |
| A0999 | Unlisted ambulance service | 0% | 30 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMARSH, LINDA (SENIOR VICE-PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Ahmc Garfield Medical Center LP | Monterey Park, CA | $17.83M |
| Ahmc Whittier Hospital Medical | Whittier, CA | $15.12M |
| Ahmc Anaheim Regional Medical | Anaheim, CA | $14.21M |
| Ahmc Monterey Park Hospital LP | Monterey Park, CA | $10.85M |
| Ahmc San Gabriel Valley Medical | San Gabriel, CA | $6.96M |
| Alhambra Hospital Medical Center, LP | Alhambra, CA | $6.90M |
| Ahmc Seton Medical Center LLC | Daly City, CA | $5.21M |
| Alhambra Hospital Medical Center, LP | Alhambra, CA | $1.57M |
| Ahmc San Gabriel Valley Medical | San Gabriel, CA | $249K |
| Alhambra Hospital Medical Center, LP | Alhambra, CA | $176K |
| Alhambra Hospital Medical Center, LP | Alhambra, CA | $34K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.